Corporate Brochure
Transcription
Corporate Brochure
REC_BROCH_2016_INGLESE_Layout 1 30/05/16 15:39 Pagina 1 REC_BROCH_2016_INGLESE_Layout 1 30/05/16 15:39 Pagina 2 A LONG SUCCESS STORY. OVER 90 YE 1926 1926 Recordati was founded in Correggio (Emilia, Italy). The company emerges from a small apothecary which Giovanni Recordati (1898-1952) transformed into an industrial concern: the “Laboratorio Farmacologico Reggiano”. 1953 In a period of economic expansion and post-war resurgence, Recordati moves the company to the current site in Milan, the most important Italian economic centre. Recordati specialties such as Antispasmina colica® (1927, antispasmodic for the gastrointestinal tract), Solvobil® (1930, laxative and colagenic), Tefamin® (1935, heart tonic, diuretic and antihypertensive) and its associations, Simpamina® (1938, stimulant) continued to perform well. 1961 An exclusive license agreement is signed with Syntex Corporation (now part of Roche), at that time at the leading edge of research into the study and synthesis of steroidal hormones. New original drugs are registered and commercialized in a number of countries: Recordil® (1959, efloxate, coronary vasodilator), Remeflin® (1962, dimefline, respiratory analeptic) and Antoral® (1977, tibezonium iodide, an oral antiseptic). In 1973 flavoxate (Genurin®/ Urispas® and other brands), a urinary anti-spasmodic still widely used, was launched. It was the first drug synthesized and developed in Italy to receive FDA approval in the USA. 1984 The company is listed on the Italian stock exchange (Borsa Italiana, now part of the London Stock Exchange). The development of the pharmaceutical business continues with the introduction of new specialties and the launch of another product originated from Recordati’s research, Lomexin® (fenticonazole), a dermatological and gynecological anti-mycotic, still widely used in clinical practice in many countries. 1995 Recordati outlines its growth and development strategy embarking on a process of internationalization. A subsidiary was established in Spain, now called Casen Recordati. 1997 First launch of Zanidip® (lercanidipine), a new antihypertensive drug entirely discovered and developed by Recordati. 1999 Recordati acquires the French pharmaceutical company Doms Adrian to establish a Group direct presence in the second largest pharmaceutical market in Europe. 2000 Expansion in France continues with the acquisition of the Bouchara pharmaceutical group. 2001 The two French companies are merged and the resulting subsidiary becomes Bouchara Recordati. Conversion of all savings shares into ordinary shares and subsequent 2:1 stock split (2001). 2002 The U.K. Medicines Control Agency granted a Product License (marketing approval) for Zanidip® (lercanidipine) 20 mg tablets. 2004 The pharmaceutical pipeline is considerably strengthened through the launch of important drugs in the cardiovascular, gastroenterology, CNS, and respiratory therapeutic fields. The 20mg strength of lercanidipine launched in a number of countries including Germany, France and Australia. 2005 Acquisition of Merckle Recordati in Germany, now Recordati Pharma. With this acquisition Recordati gains access to the largest pharmaceutical market in Europe and the third largest worldwide. Establishment of Recordati Pharmaceuticals in the United Kingdom and of Recordati Hellas Pharmaceuticals in Greece. Recordati establishes a presence in Ireland with the opening of a new active pharmaceutical ingredients plant in Ringaskiddy, County Cork. 4:1 stock split. 2006 Recordati enters the Portuguese pharmaceutical market directly through the acquisition of the Grupo Jaba companies, today Jaba Recordati. A new original Recordati product is approved. Zanipress®, a fixed combination of lercanidipine and enalapril was approved for sale by BfArM (the German medicines agency). This approval represents the beginning of the process which will result in the introduction of this new important product in all the European markets and beyond. 2007 The first launch of Zanipress®, Recordati’s new antihypertensive product which associates lercanidipine and enalapril in a fixed combination, took place in Germany. Recordati enters the orphan drug market through the acquisition of Orphan Europe, a European pharmaceutical group based in Paris dedicated to the development, registration, marketing and distribution of unique drug for the treatment of rare and orphan diseases. 90 YEARS OF ACTIVITY. 2008 Recordati acquires the French companies FIC and FIC Médical which are dedicated to the registration and the promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries. Recordati sets the base from which it will expand its activity into high growth markets. Recordati also acquired Yeni Ilaç, a well-known pharmaceutical company with headquarters near Istanbul in Turkey, a market with high growth rates. 2009 Recordati acquires Herbacos-Bofarma, a pharmaceutical company operating in the Czech and Slovak markets. 2010 European Marketing Authorization obtained for the medicinal products Urorec® and Silodyx™ 4 mg, 8 mg, hard capsules, intended for treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Carbaglu® (carglumic acid) approved by the Food and Drug Administration (FDA) in the U.S. for the treatment of NAGS deficiency. Acquisition of ArtMed International, a company dedicated to the promotion of pharmaceutical products in Romania. Positive outcome of the Decentralized Procedure for the approval of pitavastatin (Livazo®, Alipza® and other brands) in Europe. 2011 Orphan Europe, the group’s wholly-owned subsidiary dedicated to treatments for rare diseases, received European approval to extend the use of Carbaglu® (carglumic acid) to treat hyperammonaemia due to either of the three main organic acidaemias. The Group intensifies its strategy to grow in the emerging markets of Central and Eastern Europe: Recordati Polska is established in Poland and a second pharmaceutical company is acquired in Turkey, Dr. F. Frik Ilaç A.S.. Recordati acquires the brand and all rights to Procto-Glyvenol ® a product indicated for the treatment of haemorrhoids. Livazo® (pitavastatin) launched in Spain and in Portugal. 2012 Acquisition of the marketing authorizations, the trademarks and additional assets concerning six OTC pharmaceuticals for Germany. Recordati reinforces its presence in Poland with the acquisition of Farma-Projekt and consolidates its business in Russia and other C.I.S. countries with the acquisition of all rights to five well-known product lines including the addition of a dedicated sales organization. Acquisition in Italy of the leading oral care line of products bearing the Dentosan® trademark. An agreement was signed with Erytech Pharma for the commercialization and distribution of Graspa® for the treatment of Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) in Europe. Recordati acquires all rights concerning a portfolio of products indicated for the treatment of rare and other diseases in the United States of America which is now marketed there by Recordati Rare Diseases. 2013 Recordati acquires Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana (Tunis) and a modern cGMP certified production facility, which represents a strategic platform to establish a direct presence in North Africa with the objective of extending coverage also to countries in Central Africa and in the Gulf states. The Group reinforces its presence in Spain, the fifth pharmaceutical market in Europe, with the acquisition of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid, production facilities in Utebo, Zaragoza, that markets drugs mainly in the gastroenterological therapeutic area. 2014 An exclusive license agreement was entered into with Apricus Biosciences Inc., San Diego U.S.A., for the marketing and sales of Vitaros® (alprostadil), an innovative topical product for the treatment of erectile dysfunction, in certain European countries, Russia, Ukraine and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries. U.S. Food and Drug Administration (FDA) granted approval of Orphan Europe’s request for orphan drug designation for the use of Carbaglu® (carglumic acid) in the treatment of organic acidemias (OAs). A license agreement with Plethora Solutions for the commercialization of Fortacin™, a topical spray formulation of lidocaine and prilocaine for the treatment of premature ejaculation, in Europe, Russia, Commonwealth of Independent States (C.I.S.), Turkey and certain countries in North Africa was signed. 2015 The internationalization of our rare disease business went ahead with the establishment of subsidiaries in Latin America, and in particular in Brazil, Mexico and Colombia. Furthermore, Carbaglu® (carglumic acid) was authorized for sale by Health Canada as an adjunctive therapy for the treatment of acute hyperammonaemia or as maintenance therapy for chronic hyperammonaemia due to NAGS deficiency in pediatric and adult patients. 1926 | 2016 REC_BROCH_2016_INGLESE_Layout 1 30/05/16 15:39 Pagina 3 1926 | 2016 REC_BROCH_2016_INGLESE_Layout 1 30/05/16 15:39 Pagina 4 FUTURE GROWTH STEMS FROM DEEP ROOTS. All mentions and descriptions of Recordati prescription products are intended solely to inform the reader of the general nature of the Company’s activities with the sole institutional objective of presenting the Company and the Group. They are not intended to promote the use, or to indicatethe advisability of using, Recordati prescription products, in compliance with existing law. REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 1 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 2 2 | RECORDATI RECORDATI A RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP Thanks to its flexibility and to the established capability of its management, the Recordati group is able to operate successfully in a market in continuous evolution and to identify fitting business opportunities as they arise. REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 3 A RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP | 3 A MODERN AND DYNAMIC INTERNATIONAL GROUP Recordati is a modern and dynamic international pharmaceutical group based in Milan, italy. Recordati is listed on the Italian Stock Exchange (London Stock Exchange Group) since 1984. It has grown constantly since 1926 thanks to the success of its products and to the implementation of a decisive internationalization policy through a focused strategy of acquisitions and license agreements. Recordati produces and promotes innovative medicines worldwide including both products for primary care therapies and treatments for rare diseases. In addition to the marketing of specialties generated by its original research, the Recordati group is the european partner of leading international pharmaceutical companies. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 4 4 | A RENOWNED INTERNATIONAL PHARMACEUTICAL GROUP RECORDATI IN A CHANGING MARKET With subsidiaries in the main European countries, in U.S.A., in some Latin American countries, in Russia and the Commonwealth of Independent States, in Turkey and in Tunisia, Recordati is interested in developing its business both in the Central and Eastern European countries and in the so-called MENA (Middle East and North Africa) countries where pharmaceutical markets show potential for growth. Recordati constantly enhances its therapeutic offering through the development of its product pipeline mainly in the area of urological disorders and in the field of rare diseases. RECORDATI, A GROWING COMMITMENT TO THE TREATMENT OF RARE DISEASES Recordati is committed to the improvement of the quality of life of people suffering from rare diseases and works together with patients and their families, with doctors and with the support of a highly specialized internal team. The Recordati group operates worldwide through its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases who share the conviction that each person with a rare disease has the right to the best possible treatment. Recordati develops, produces and sells drugs for the treatment of rare diseases, and operates worldwide in a highly specialized market with a significant growth potential. REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 5 RECORDATI THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE The proven ability for creating profitable partnerships with important players in the pharmaceutical sector will continue to support the Recordati group in its quest to identify new partners and finalize new license agreements for the development of high value medicinal products. A GROWING PRESENCE IN NEW MARKETS In the future the Recordati group will continue its focus on the development of its international business and in particular in pharmaceutical markets with growth potential such as Russia, Eastern Europe, Turkey, Tunisia and countries around the Mediterranean. Recordati will continue to concentrate its activity in Europe, which is the second largest pharmaceutical market in the world, and to make its products for the treatment of rare diseases available worldwide including the U.S.A., the first largest market, and some Latin American countries. | 5 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 6 6 | THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE A RICHER PRODUCT PORTFOLIO The launch of innovative new products, the enhancement of its product portfolio with specialties from its own research and development or from targeted license agreements or specific acquisitions, will boost the group’s growth. The extensive geographical coverage, an efficient field force of medical representatives and orphan drug specialists, the significant competence in handling regulatory processes, the profound know-how in the handling of highly specialized products, all make the Recordati group an ideal partner for the development and marketing of new products in Europe. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 7 THE RECORDATI GROUP BETWEEN PRESENT AND FUTURE CONSTANT INVESTMENT IN RESEARCH AND INNOVATION Recordati is committed towards the innovation and marketing of high value added products and therefore constantly develops new medicines and believes research and development is a fundamental basis for its growth. Dedication and scientific rigor are always behind Recordati’s specialties and self-medication products which are also produced with the highest levels of quality and safety. The “Arrigo Recordati International Prize for Scientific Research” is a further testimony of the Recordati Group’s commitment to support the development of new innovative therapies. R&D EXPENSES Millions of Euro 85.2 74.7 76.7 63.4 56.0 2011 2012 2013 2014 2015 | 7 REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 8 8 | RECORDATI TODAY’S NUMBERS 2015 was a very favourable year for the group and a number of initiatives were pursued or the company’s future development. REVENUE 1,047.7 millions of euro NET INCOME 198.8 millions of euro NET FINANCIAL POSITION (88.7) millions of euro SHAREHOLDERS‘ EQUITY 870.0 millions of euro DIVIDEND 0.60 euro per share EMPLOYEES 4,000 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 9 TODAY’S NUMBERS REVENUE Millions of Euro 1,047.7 INTERNATIONAL BUSINESS GROWTH TREND OPERATING INCOME Millions of Euro | 9 OPERATING INCOME AS % OF REVENUE 278.5 987.4 26.6% 79.8% 941.6 231.0 828.3 77.8% 762.0 195.4 163.5 167.0 75.7% 23.4% 73.5% 21.5% 20.8% 70.9% 2011 2012 2013 2014 2015 NET INCOME 20.2% 2011 2012 2013 2014 2015 NET INCOME AS % OF REVENUE Millions of Euro 198.8 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 DIVIDEND PER SHARE BALANCE SHEET Euro At 31 December 2015 0.60 19.0% 18.56% Current Liabilities 0.50 161.2 40.35% Current Assets 22.22% 133.7 Non-Current Liabilities 116.4 118.5 16.3% 0.33 0.30 0.30 59.65% Non-Current Assets 15.3% 59.22% Shareholders’ Equity 14.3% 14.2% 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 2011 2012 2013 2014 2015 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 10 10 | RECORDATI GEOGRAPHICAL PRESENCE 135 COUNTRIES Subsidiaries Branches and other forms of territorial presence Countries where Recordati products are sold (under license or exported) REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 11 GEOGRAPHICAL PRESENCE GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL SALES (First quarter 2016) 21.1% Italy 6.3% Spain 9.8% France 5.4% North Africa 8.8% USA 3.4% Portugal 8.3% Germany 2.8% Other West Europe 7.7% Turkey 2.7% Other CEE 6.6% Russia, Ukraine and other C.I.S. 17.1% Other International sales | 11 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 12 12 | RECORDATI RECORDATI’S SUCCESSFUL PRODUCTS A number of innovative high value added specialties comprise a large and qualified product portfolio. The Recordati group: makes available to healthcare professionals and patients numerous medicines belonging to various therapeutic areas; boasts an important presence in the areas of cardiovascular and urological disorders for which it offers new treatments; markets products originated by its own research and by specific license agreements by promoting a wide range of innovative drugs. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 13 RECORDATI’S SUCCESSFUL PRODUCTS PHARMACEUTICAL SALES BY THERAPEUTIC AREA (2015) 16.9% Treatments for Rare Diseases 15.1% Gastrointestinal and Metabolism 25.9% Cardiovascular 2.3% Dermatology 3.7% Ginecology 2.6% Anti-infective 8.4% Muscolo-skeletal, Analgesia 3.9% Central Nervous System 6.7% Respiratory 3.0% Sense organs 9.7% Urology 1.8% Others COMPOSITION OF REVENUE BY BUSINESS (2015) 40.3% Corporate Products 14.6% Treatments for Rare Diseases 16.9% OTC 23.6% Subsidiaries’ Local products 1.2% Other Revenue 3.4% Pharmaceutical Chemicals | 13 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 14 14 | RECORDATI’S SUCCESSFUL PRODUCTS CORPORATE PRODUCTS Main specialties marketed by the group: ZANIDIP® [CORIFEO®/LERCADIP®] (lercanidipine) antihypertensive ZANIPRESS® [ZANEXTRA®/LERCAPREL®/LERCARIL®] (lercanidipine + enalapril) antihypertensive UROREC® (silodosin) benign prostatic hyperplasia LIVAZO® [ALIPZA®] (pitavastatin) hypercholesterolaemia TERGYNAN® gynecological infections ® Sodio picosolfato - Magnesio ossido leggero - Acido citrico anidro CITRAFLEET® and FOSFOSODA® bowel evacuants LOMEXIN® [FALVIN®] (fenticonazole) antimycotic HEXA LINE OF PRODUCTS (biclotymol) antibacterial for infections of the oral cavity REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 15 RECORDATI’S SUCCESSFUL PRODUCTS PROCTO-GLYVENOL® (tribenoside) haemorrhoids URISPAS® [GENURIN®] (flavoxate) urinary tract muscle relaxant TRANSACT® LAT (flurbiprofen transdermal patch) anti-inflammatory RUPAFIN®/WYSTAMM® (rupatadine) antihistamine CASENLAX®/LAXBENE® and FLEET ENEMA® constipation and bowel cleansing KENTERA® (oxybutynin transdermal patch) hyperactive bladder OXYBUTYNIN TRANSDERMAL PATCH Lopresor ® LOPRESOR® (metoprolol) antihypertensive MUVAGYN® vaginal dryness VITAROS®/VIRIREC® (alprostadil) erectile dysfunction | 15 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 16 16 | RECORDATI’S SUCCESSFUL PRODUCTS SUBSIDIARIES’ LOCAL PRODUCTS Some products or product lines marketed locally by Recordati’s subsidiaries detain prominent positions in their markets of reference. GEOGRAPHICAL COMPOSITION OF PHARMACEUTICAL REVENUE (2015) 54.4% Western Europe 10.2% Central and Eastern Europe 11.6% Turkey and North Africa 8.1% USA 15.7% Others REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:36 Pagina 17 RECORDATI’S SUCCESSFUL PRODUCTS In addition to its consolidated presence in the cardio-metabolic area, Recordati in Italy offers innovative treatments in urology and for disorders of and gastrointestinal system as well as modern analgesics. In France Bouchara Recordati is the exclusive licensee for the production and commercialization of methadone, a synthetic opioid analgesic, used in disintoxication from opiates and in maintenance programmes. The company has also developed an important international presence in the Maghreb area and in French-speaking Africa and Asia. A dynamic export and promotion business distributes its specialties in more than 30 countries. Recordati Pharma in Germany supplies first class products to orthopaedic specialists and to gastroenterologists, in particular as related to chronic inflammatory intestinal disorders such as Crohn’s disease and ulcerative colitis. | 17 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 18 18 | RECORDATI’S SUCCESSFUL PRODUCTS Rusfic, Recordati Ukraine and FIC Médical, our organizations operating in Russia, Ukraine and CIS markets have very successfully developed the market for a product indicated for the topical treatment of vaginal infections which boasts a leading position in the class of gynaecological anti-infective and antiseptic drugs. In Turkey Recordati Ilaç markets a diversified product portfolio well appreciated by the practitioner, mainly comprising products for the treatment of disorders of the urinary tract and other urological disorders. In Tunisia, Opalia Pharma, one of the largest local pharmaceutical companies, markets branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 19 RECORDATI RECORDATI AND THE TREATMENT OF RARE DISEASES The acquisition and diffusion of specific scientific knowledge is fundamental for the identification of a rare disease and is of great importance in the research for new therapies. www.recordatimalattierare.it Rare diseases bring great suffering to millions of affected people worldwide. A rare disease is defined as a condition that affects fewer than 5 per 10,000 inhabitants in Europe or fewer than 200,000 Americans in the U.S.A.. There are more than 7,000 known rare diseases but today treatment exists for only 200-300 of these. | 19 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:47 Pagina 20 20 | RECORDATI AND THE TREATMENT OF RARE DISEASES The Recordati group operates in the rare disease segment worldwide through its dedicated subsidiaries Orphan Europe and Recordati Rare Diseases. Orphan Europe operates globally through a network of subsidiaries in Europe and in the Middle East and a number of marketing agreements. It develops, produces and markets drugs exclusively for the treatment of rare diseases. Orphan Europe is one of the most important companies in Europe by number of orphan drugs with marketing approval. Recordati Rare Diseases is the company through which the group operates in the rare disease segment in the U.S.A. New subsidiaries were established in some Latin American countries. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 21 RECORDATI AND THE TREATMENT OF RARE DISEASES Highly trained specialists and a scientific support team collaborate constantly with doctors and healthcare professionals, with patient groups and families, to treat and improve the quality of life of people suffering from these diseases worldwide. Thanks to a unique distribution system and to specialists dedicated to the promotion and distribution of these products, the group is able to reach patients in their home countries. www.orphan-europe.com The Recordati group makes available to doctors and their patients a team of highly trained specialists and a number of specific drugs. | 21 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 22 22 | RECORDATI AND THE TREATMENT OF RARE DISEASES OUR DRUGS FOR RARE DISEASES Normosang®/Panhematin®(USA) human hemin Treatment of acute attacks of hepatic porphyria Carbaglu® carglumic acid Treatment of hyperammonemia due to N-acetylglutamate synthase deficiency (NAGS deficiency) and some organic acidaemias (isovaleric acidaemia, methylmalonic acidaemia and propionic acidaemia) Cosmegen® dactinomycin injectable Treatment of three rare cancers Pedea®/NeoProfen® (USA) ibuprofene iv Treatment of patent ductus arteriosus (PDA) Cystadane® betaine anhydrous Treatment of homocystinuria Cystadrops® cysteamine chlorhydrate Submitted for approval for the treatment of ocular manifestations of cystinosis Cystagon® cysteamine bitartrate Treatment of nephropathic cystinosis Vedrop® tocofersolan Treatment or prevention of vitamin E deficiency in paediatric patients and adolescents suffering from congenital or hereditary chronic cholestasis Wilzin® zinc acetate Treatment of Wilson’s disease Adagen® pegademase bovine Enzyme replacement therapy for the treatment of severe combined immunodeficiency disease associated with adenosine deaminase deficiency (SCID-ADA) REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 23 RECORDATI AND THE TREATMENT OF RARE DISEASES Recordati’s commitment to making its products available to patients suffering from rare diseases was recognized by the National Organization for Rare Disorders (NORD) in the U.S.A. with its 2011 “Corporate Award”. This important award was granted in recognition of the introduction into the United States of Carbaglu®, the first specific treatment approved by the FDA (Food and Drug Administration) for NAGS deficiency, a very rare inherited metabolic disease. The important results obtained by Orphan Europe (Recordati group) in improving the diagnosis and management of rare diseases were recognized by EURORDIS (European Organization for Rare Diseases) with an award presented during the celebration of the 2014 Rare Disease Day. The award also distinguishes its established track record in the field of orphan drug development and its engagement with the rare disease community. Orphan Europe achieves this through work to establish scientific networks, engaging with patient organizations and its staff volunteering program. | 23 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 24 24 | RECORDATI AND THE TREATMENT OF RARE DISEASES The Recordati Rare Diseases Fondation d’entreprise targets specialized healthcare professionals and its aim is to improve and to spread currently available knowledge on rare diseases. The organization promotes scientific collaboration, the sharing of experiences and knowledge among sector specialists and the development of new ideas. Every year the Academy proposes theoretical and practical courses as well as e-learning online courses which aim to provide physicians, world-wide, with clinically useful and the most up-to-date information concerning current knowledge and recommendations for care. Recordati is committed to supporting families affected by these diseases through the research and development of new therapies and through the diffusion of specific scientific knowledge within the medical community. REC_BROCH_2016_ING_OK_Layout 1 06/06/16 11:29 Pagina 25 RECORDATI | 25 THE RECORDATI GROUP AND ITS SELF-MEDICATION PRODUCTS The Recordati group is also present in the self-medication market segment with well-known brands. It is committed to the improvement of quality of life by offering a choice of successful products. Recordati is on the constant look-out for new treatments to offer patients and has extended its OTC portfolio. All Recordati’s pharmaceutical specialties and self-medication products are characterized by high levels of quality and safety in all countries. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 26 26 | RECORDATI RESEARCH AND INNOVATION AT RECORDATI The introduction of new products, both through our discovery programs as well as through alliances with other companies: this is Recordati’s commitment and is a fundamental premise for its growth. The Recordati group constantly develops new specialties originated either internally or acquired through development agreements with other pharmaceutical companies. Commitment, scientific rigor, flexibility and highly specialized personnel allow Recordati to develop new treatments and to count on an innovative product pipeline. Recordati’s research and development activities are mainly focused on generating innovative treatments in the areas of urological and rare diseases. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 27 RESEARCH AND INNOVATION AT RECORDATI | 27 PRODUCT DEVELOPMENT PIPELINE Name Originator VITAROS® Apricus Erectile dysfunction Approved by a number of health authorities in Europe CARBAGLU® Recordati Organic acidemias (OA) Approved in EU Phase III in U.S.A. CARBAGLU® Recordati Hyperammonaemia New formulations CYSTADROPS® Recordati Ocular cystinosis Filed in EU FORTACIN™ Premature ejaculation Variation of EU approval completed Cancer related pain in cases of resistance or intolerance to opioids Filed in France Plethora Solutions methadone Indication Development Status CITRAFLEET® Recordati/Casen Preparation for colonoscopy in patients at risk of intestinal polyps MA variation approved in EU GRASPA® Erytech Acute lymphoblastic leukemia (ALL) in patients with first recurrence of Philadelphia chromosome negative ALL Filed in EU Acute myeloid leukemia (AML) in patients >65 unfit for chemotherapy Phase II b Overactive bladder in patients with spinal lesions Phase I/II in EU REC 0438 Recordati/UFPeptides REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 28 28 | RECORDATI PARTNERING WITH THE RECORDATI GROUP Thanks to its capability in developing successful relationships, Recordati has enacted an intelligent policy of partnering with companies of high standing in the pharmaceutical segment and made targeted acquisitions in markets characterized by high growth potential thus generating value for itself and its partners. Recordati has a strong track record in generating value through partnerships with other pharmaceutical companies, local or global players. It is committed to generating further growth through mutually beneficial R&D collaborations, license agreements, acquisitions. It covers directly around 80% of the European pharmaceutical market and has a strong and growing interest in new markets. It has affiliates in Western Europe (Italy, France, Germany, Greece, Portugal, Spain, United Kingdom and Ireland), in Central Europe (Poland, the Czech Republic, Slovakia, Romania), in Russia and the other CIS countries, in Ukraine as well as in the U.S.A., in Turkey, in Tunisia and in some Latin American countries. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 29 PARTNERING WITH THE RECORDATI GROUP The group disposes of a strong team of experienced sales and marketing professionals. Through its wholly owned subsidiary Orphan Europe and its U.S. subsidiary Recordati Rare Diseases, Recordati is also dedicated to the development and sale of drugs for the treatment of rare diseases. Recordati has proven R&D experience in developing treatments for cardiovascular, urology disorders and rare diseases. Its proven capabilities in the management of regulatory procedures and clinical trials in the EU, MENA (Middle East and North Africa) and in the USA make Recordati an ideal partner for the development and commercialization of new products. | 29 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 30 30 | PARTNERING WITH THE RECORDATI GROUP The extensive know-how acquired and dedicated industrial resources allow the company to fully cover the manufacturing chain, from active ingredient to finished product, in its own facilities in Italy, France, Ireland, Spain, Turkey and Tunisia. The financial solidity of the group allows it to support targeted R&D investments. The Group, which covers around 80% of the European pharmaceutical market with a direct presence also in the USA, proposes itself as an ideal partner for the development and commercialization of new products in its territories. REC_BROCH_2016_ING_OK_Layout 1 07/06/16 09:46 Pagina 31 PARTNERING WITH THE RECORDATI GROUP SELECTED PARTNERSHIPS Licensor Trademark Active Ingredient Rights for: Actavis Kentera® oxybutynin TDS 29 European countries Almirall Cidine® cinitapride Spain Amdipharm TransAct®LAT flurbiprofene LAT Italy, Portugal Apricus Vitaros® alprostadil Spain, Ireland, Portugal, Greece, some Eastern European countries, Commonwealth of Independent States, Ukraine, Turkey, some African countries. Ipsen Tenstaten® cicletanine France Kissei Urorec®/Silodyx®/Silosin® silodosin Europe & Others Kowa Livazo®/Alipza® pitavastatin Europe (exc. UK, Germany) Merck KGaA Cardicor® bisoprolol Italy MSD Isocef® ceftibuten Italy Ono-UCB Alprostar® PGE 1 Alpha Italy Plethora Solutions Fortacin™ lidocaine+prilocaine Europe, Russia, CIS, Turkey, North Africa Rottapharm/Madaus Dermatrans®/Epinitril® nitroglicerine TDS Spain, France Takeda Peptazol® pantoprazole Italy Uriach Wystamm®/Rupafin® rupatadine France, Germany, Italy | 31 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 32 32 | RECORDATI CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES THE ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH The Arrigo Recordati International Prize for Scientific Research was established in the year 2000 in memory of the Italian pharmaceutical entrepreneur Arrigo Recordati who strongly believed in the power of research to drive the development of the pharmaceutical industry and provide products beneficial to public health. The Prize is an international award which aims to promote scientific research in the field of cardiovascular disease. It consists in 100,000 Euros being awarded to a distinguished scientist for his or her commitment and accomplishments in this area. Each edition of the Prize, which is presented every two years, is dedicated to a specific theme. More than 200 international societies and organizations specializing in the areas of cardiology and internal medicine, are invited to nominate candidates that they feel deserve the award. The winner is chosen by a Jury composed of experts with high international standing and is announced during an awards ceremony. 2017 ARRIGO RECORDATI INTERNATIONAL PRIZE FOR SCIENTIFIC RESEARCH, NINTH EDITION. • The theme chosen for the next edition of the Prize, which will take place in 2017, is: “BIOLOGICAL THERAPIES FOR THE TREATMENT OF DISEASES AND CONDITIONS WITH HIGH CARDIOVASCULAR RISK”. • The winner of the Prize will be announced during an awards ceremony scheduled to take place in Milan, Italy, on June 17, 2017, during the ESH (European Society of Hypertension) Annual Meeting. www.recordati.com/prize REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 33 CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES THE WINNERS OF PREVIOUS EDITIONS: 1st Edition 2001 HYPERTENSION Giuseppe Mancia, Professor of medicine and chairmanof the department of clinical medicine, prevention and applied biotechnologies of the University of Milan – Bicocca (Italy). 2nd Edition 2003 HEART FAILURE Jay N. Cohn, Professor of Medicine, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis - John K. Kjekshus, MD, PhD, Professor of Medicine, Department of Cardiology, Rikshospitalet, University of Oslo, Oslo 3rd Edition 2005 SUDDEN CARDIAC DEATH Leonard A. Cobb, MD, Hemeritus Professor, American College of Cardiology, Seattle WA, USA. Peter J. Schawartz, MD, Professor and Chairman, Department of Cardiology, Policlinico San Matteo IRCCS, Pavia, Italy Hein J. J. Wellens, MD, Honoré Retired Professor, University of Maastricht; Director of Arrhythmology, Interventional Electrophysiology and Cardiology, University of Maastricht, Maastricht, The Netherlands. 4th Edition 2007 INTERVENTIONAL CARDIOLOGY AND ISCHEMIC HEART DISEASE Patrick W. Serruys, Professor of Interventional Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands 5th Edition 2009 IMAGING DIAGNOSTICS IN HEART DISEASE Valentin Fuster, Director of Mount Sinai Heart - New York, U.S.A. 6th Edition 2011 PRENATAL CONGENITAL HEART DISEASE Lindsay Allan, Consultant - King’s College, London, UK 7th Edition 2013 THE PIVOTAL ROLE OF MICROCIRCULATION IN SYSTEMIC AND ORGAN DISEASES Filippo Crea, Professor of Cardiology - Università Cattolica Policlinico “Agostino Gemelli” of Rome, Italy 8th Edition 2015 SECONDARY PREVENTION AND RISK REDUCTION STRATEGIES FOR PATIENTS WITH CARDIOVASCULAR DISEASES. John Joseph Valentine McMurray, Professor of Medical Cardiology and convener for clinical research in the Institute of Cardiovascular & Medical Sciences at the University of Glasgow, Scotland, UK. Salim Yusuf, Professor of Medicine, Executive Director of the Population Health Research Institute (PHRI), McMaster University, Hamilton, Canada. | 33 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 34 34 | CORPORATE SOCIAL RESPONSIBILITY ACTIVITIES Every year Recordati supports a number of associations dedicated to assisting sick people, to the improvement of patients’ quality of life, and to new research projects. Social, cultural and environmental institutions who operate seriously and with passion on a daily basis are generously assisted. ASSISTANCE AND RESEARCH • AISAC - Association for information on and the study of Achondroplasia • ANLAIDS - National AIDS Association • UROMENDA (Hospital de Mendaro) Urology Association • Asociación Neuroinvest (Hospital Virgen de la Macarena Sevilla) • Association for the development of Endocrinology and Nutrition (Hospital Universitario Puerto Real Cádiz) • Associazione Italiana GLUT1 - Association for GLUT 1 deficiency syndrome • Association Chirurgie Robotisee et Mini Invasive • Association Francaise Urologie • Association pour l'etude des maladies de l’appareil urinaire • Associazione Bianca Garavaglia - study and treatment of pediatric tumors • Associazione contro la leucemia e le altre emopatologie maligne per la ricerca clinica e la terapia domiciliare Progetto EMO-CASA - leukemia and other hemooncology diseases • Associazione Correre per la Speranza - Cancer association • Cardiología Hospital Granollers • Club de Reflexion des Cabinets et Groupes d'hepatogastroenterolgie • Comitato Maria Letizia Verga - Study and treatment of pediatric leukemia • Conseil National Professionnel d'hepato-gastro-enterologie • Deutsche Hochdruckliga - German association of hypertension • DKMS Deutsche Knochenmarkspenderdatei gemeinnützige Gesellschaft mbH - support for activity by the University of Leipzig on bone marrow typing • Fondazione Benedetta D'Intino - Psychophysical suffering in childhood • Fondazione Manuli - Assistance for Alzheimer patients • Fundació Clinic (Hospital Clínico Barcelona) • Fundació Institut D'Investigació biomedica de Bellvitge (IDIBELL) • Fundación de Ayuda a la Investigación sobre Hipertensión Arterial - research in hypertension • IGOST Interdisziplinäre Gesellschaft für orthopädische / unfallchirurgische und allgemeine Schmerztherapie Interdiciplinary association for pain management • Institut Formation & Recherche en Endoscopie Digestive • Sociedad Española de Diabetes • Sociedad Española de Médicos de Atención Primaria (SEMERGEN) - Spanish Society for primary care • Societe Francaise de Cardiologie • SuperAbile - Association for the rights of the disabled CULTURE AND THE ENVIRONMENT • Associazione Culturale “G. DOSSETTI” - progetto “Officina Malattie Rare” - Cultural projects on rare diseases • Collegio Ghislieri - University college • Coro San Pietro in Formis • FAI - Italian Foundation for the Environment • Fondazione Milano per la Scala • Orchestra Sinfonica G. Verdi RESEARCH • Associazione Amici del Centro Dino Ferrari - research in neuromuscular and neurovegetative diseases • Associazione Amici di URI - Urological research institute • Fondazione Ricerca e Innovazione su Ipertensione e Protezione Cardiovascolare – Foundation for research and innovation in hypertension and cardiovascular protection • The Arrigo Recordati International Prize for scientific research • Samuel e Barbara Sternberg Foundation - cancer research and treatment SOCIAL • A.I.O.S.S - A.I.O.S.S - Association for the integration and guidance of disadvantaged people • Asiens vergessene Kinder - Association for social and medical support of disadvantaged children and adolescents • Associazione Il Bruko - Volunteering and solidarity to help the elderly and sick children • Associazione Pensiero Celeste - support in perinatal mourning • Associazione Sesamo - support for people with handicaps • Associazione Tutela Malati Psichici (ATAP) - protection for psychiatric patients • BIR - Bambini in Romania - protection of minors • Comunità di San Patrignano - support and rehabilitation in drug addiction • Deutsche Akademie für Sportmedizin - Academy for the promotion of education in sports and rehabilitative medicine • Dynamo Camp - Recreation campus for children suffering from serious chronic diseases • Fond. Piero e Lucille Corti onlus - support for the Lacor Hospital in Uganda • Fondazione Nuovo Fiore in Africa - training activities • GastroLiga - German Society of gastrointestinal diseases • Lega del Filo d'Oro - support for the deaf and blind • LifeNet Onlus - Association for the sanitary and social support of populations in difficulty • Naevus Italia Onlus - National Association of subjects born with giant congenital melanocytic nevus • Oeiras Luchapa Association - support for the homeless • Ronda della Carità e Solidarietà - support for the poor • Semi di Pace International - humanitarian society • Solfraterno - support for poor families • SSD Volare - support for the disabled • Stiftung LebensBlicke - Foundation dedicated to early diagnosis in colorectal cancer • Temporary Foster Home in Barreiro • Traumateam - Emergency medicine aid team • Università Cattolica - Fund raising for African students • Università degli Studi di Milano - CusMiBio - formative project in secondary schools • Volontariato Caritas Salesiani - help for the disadvantaged THROUGH ORPHAN EUROPE AND RECORDATI RARE DISEASES, THE RECORDATI GROUP ALSO, SUPPORTS A NUMBER OF OTHER ASSOCIATIONS: • 1st University paediatric Dept • ABASP (Association de l'avancement des sciences pédiatriques) • AFAG • AIRG (Association pour l'Information et la Recherche sur les maladies Rénales Génétiques) • AJP (Association des Juniors en Pediatrie) • ALLIAGE (Association Lariboisière des affectations génétiques et Environementales du Cuivre et Autres Metaux) • American Heart Association • American Porphyria Foundation • ARCAMMHE (Association Regionale de Champagne Ardenne pour le dépistage et la prévention des maladies métaboliques des handicaps de l'enfant) • ASCR (Association des services du CHU de Rouen) • ASPIDA ZOIS • Associazione Italiana Cistinosi • Associazione Malattia di Wilson • British Porphyria Association • Centre français des porphyries • Cystinosis Foundation • Cystinosis Selbsthilfegruppe • ERE (Enfance Recherche Espoir) • Fondation maladies rares • Fondation Necker • Global Genes • GrIP Onlus Gruppo Italiano Porfiria • Healthwell Foundation • Karathanas Brothers • KIDIGO (Kidney Disease Improving Clinical Outcomes) • KRIKOS ZOIS • National Urea Cycle Disorders Foundation • Network of Rare Blood Disorder Organizations Alberta, Canada • NORD (National Organization for Rare Disorders) • PESPA • Rare Disease Legislative Advocates (RDLA) • Raríssimas - Associação Nacional de Deficiências Mentais e Raras • Réseau Européen Maladies Rares et Psychiatrie • Serious Fun Camp • SFEIM (La société française pour l’étude des erreurs innées du métabolisme) • Société Francophone pour l'Etude de la Maladie de Wilson REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 35 RECORDATI | 35 PHARMACEUTICAL CHEMICALS Recordati uses a broad range of technologies to produce competitively maintaining the highest quality standards. RECORDATI’S PHARMACEUTICAL CHEMICALS BUSINESS FOCUSES ON: satisfying the requirements of the pharmaceuticals business, striving for maximum product quality, strengthening its presence in highly regulated markets (the United States, Europe and Japan), safety of production processes, protection of the environment, health and safety in the workplace. PHARMACEUTICAL CHEMICALS Geographical breakdown of 2015 revenues 46.7% Europe 31.2% America 16.9% Australasia 5.2% Africa REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 36 36 | RECORDATI PRODUCTION SITES The Recordati group has a number of production sites: two dedicated to the production of pharmaceutical chemicals and six for pharmaceutical manufacturing. PHARMACEUTICAL CHEMICAL PLANTS Recordati’s pharmaceutical chemical production sites are equipped with modern plant and their research laboratories are fitted with the latest equipment. A vast range of technologies, skills and expertise in the field of organic synthesis is employed to enable the quick and effective study of new processes from the research stage through to final industrialization. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 37 PRODUCTION SITES Campoverde d’Aprilia (Italy) • This plant is one of the most important producers in the world of verapamil, phenytoin, papaverine and dimenhydrinate. • Its main purpose is to supply the active ingredients for the group’s proprietary specialties, but it is also an established independent producer of active ingredients and intermediates for the pharmaceutical industry internationally. • The United States is the main market for its production. • The site covers a surface of 380,000 sq.m with a covered area of 35,000 sq.m., and produces approximately 650 metric tons per year of finished goods and approximately 5,000 metric tons of semi-finished goods are handled internally each year. • Investments have been made for additional productions, 12 new reactors and a latest generation three stage distillation unit were installed to further enhance production capacity. • It operates in compliance with Current Good Manufacturing Practices (cGMP) and in conformity with the most stringent international environmental regulations. The Plant Environmental Management System is certified according to the UNI EN ISO 14001:2004 by Det Norske Veritas Italia (DNV). Cork (Ireland) • A dedicated plant was constructed in Cork in Ireland to guarantee adequate and continuous supplies of the active ingredient lercanidipine, an important original Recordati drug. • This facility boasts automated process control systems which ensure constant high quality production. • Received the 2012 National Energy Efficiency Award which is promoted by the sustainable Energy Authority of Ireland. | 37 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 38 38 | PRODUCTION SITES PHARMACEUTICAL MANUFACTURING PLANTS Recordati’s six pharmaceutical production facilities all operate in full compliance with environmental protection regulations and with current Good Manufacturing Practices (cGMP). They are situated in Italy, France, Turkey, Spain, Tunisia and the Czech Republic. • The Milan (Italy) site occupies a surface of 21,000 sq.m. and produces 58 million packs per year. • The plant at Saint Victor (France) covers a surface of 6,750 sq.m. and produces 35 million packs per year. • The Turkish at Esenyurt site occupies a surface of approximately 14,000 sq.m. and produces 40 million packs per year, of which 20% is dedicated to third party production. This plant will soon be replaced by the new manufacturing site in Cerkezkoy which has a production capacity of 80 million packs per year. • The Spanish plant is situated near Zaragoza, it occupies a surface of approximately 8,800 sq.m. and produces around 12 million packs a year. • The Tunisian plant is situated near Tunis, it occupies a surface of approximately 7,500 sq.m. and produces around 17 million packs a year for the local market and for some of the countries in the Arabian peninsula. • The plant in the Czech Republic produces a total of 2.5 million packs per year, some of which for third parties. REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 39 RECORDATI THE RECORDATI SHARE Recordati is listed on the Italian Stock Exchange (London Stock Exchange group) since 1984. DIVIDEND PER SHARE YEAR PRINCIPAL SHAREHOLDERS 2006 € 0.185 2007 € 0.215 2008 € 0.25 2009 € 0.275 2010 € 0.275 2011 € 0.30 2012 € 0.30 2013 € 0.33 2014 € 0.50 2015 € 0.60 THE RECORDATI SHARE AT 31 DECEMBER 2015 (2015) 51.8% 46.2% FIMEI* Free Float Listing: Borsa Italiana Blue Chip segment, healthcare ISIN Code : IT 0003828271 Ticker: Bloomberg REC IM, Reuters RECI.MI Indexes: FTSE Italia Mid Cap Index FTSE Italia All-Share Pharmaceuticals & Biotechnology Index ICB Code 4570 2.0% Treasury Stock * FIMEI is 100% owned by the Recordati family Share Capital: 209,125,156 common shares Nominal value: € 0.125 per share EPS (diluted): € 0.951 Dividend per share: € 0.60 | 39 May 2016 REC_BROCH_2016_INGLESE_Layout 1 31/05/16 16:37 Pagina 40 Produced by: Recordati S.p.A. Concept and graphic design: Graphicamente Milano Photos: Archivio Recordati, Niccolò Biddau, Riccardo Sarri, Shutterstock images REC_BROCH_2016_INGLESE_Layout 1 09/06/16 10:39 Pagina 41 THE GROUP’S OFFICES ITALY IRELAND RECORDATI S.p.A. Via M. Civitali, 1 - 20148 Milan Ph. +39 02 48787.1 Fax +39 02 40073747 www.recordati.com RECORDATI IRELAND Ltd Raheens East - Ringaskiddy Co. Cork Ph. +353 21 437 94 00 Fax +353 21 4379.264 Pharmaceutical chemical plant: Via Mediana Cisterna, 4 04011 Campoverde di Aprilia (LT) Ph. +39 06 92900010 Fax +39 06 92902016 MEXICO INNOVA PHARMA S.p.A. Via M. Civitali, 1 - 20148 Milan Ph. +39 02 48787.1 Fax +39 02 48787235 COLOMBIA RECORDATI RARE DISEASES COLOMBIA S.A.S. Cra 7 N° 127 - 48 Oficina 1202 Edificio 128 Centro Empresarial Bogotá D.C. Colombia Ph: +57 1 6472780; + 57 1 6474316 CZECH REPUBLIC AND SLOVAKIA HERBACOS RECORDATI S.R.O. Kutnohorská 11/57 109 00, Praga 10 - Dolní Mêcholupy Ph. +420 227 200 722 Fax +420 227 200 777 Email: [email protected] www.recordati.cz FRANCE BOUCHARA-RECORDATI S.A.S. LABORATOIRES BOUCHARA RECORDATI S.A.S. Immeuble "Le Wilson" 70, avenue du Général De Gaulle 92800 Puteaux Ph. +33 1 45191000 Fax +33 1 47560246 Pharmaceutical plant: Parc Mécatronic - 03410 Saint Victor Ph. +33 4 70037900 Fax +33 4 70037890 GERMANY RECORDATI PHARMA GmbH Eberhard-Finckh-Str. 55 89075 Ulm Ph. +49 731 7047.0 Fax +49 731 7047.297 www.recordati.de RECORDATI RARE DISEASES S.A. de C.V. Avenida Patriotismo 201 Piso 4-414, Col. San Pedro de los Pinos C.P. 03800 Distrito Federal, Mexico Ph. +52558852-7427 www.orphan-europe.com POLAND RECORDATI POLSKA SP. Z O.O. Ul. Królewska, 16 00-103 Varsavia Ph. +48 22 206 84 50 Fax +48 22 206 84 51 PORTUGAL JABA RECORDATI S.A. LABORATORIOS CASEN FLEET S.L.U. Lagoas Park, Edificio 5, Torre C, Piso 3 2740-298 Porto Salvo Ph. +351 21 4329.500 Fax +351 21 9151.930 www.jaba-recordati.pt ROMANIA RECORDATI ROMÂNIA S.R.L. 28A Stelutei Street - Sector 1 - Bucarest Ph. +40 21 667 17 41 - 2 Fax +40 31 405 57 42 www.recordati.ro RUSSIA AND C.I.S. RUSFIC LLC World Trade Centre Office building 2, entrance 7, offices 605-608 Krasnopresnenskaya emb. 12 Mosca, 123610, Russia Ph. +7 495 258 20 06 Fax +7 495 258 20 07 Email: info@rusfic.com FIC MEDICAL S.a.r.l. Immeuble "Le Wilson"70, avenue du Général de Gaulle 92800 Puteaux, Francia Ph. +33 1 45 19 11 00 Fax +33 1 45 19 10 83 www.rusfic.ru Plant: Autovia Logroño km. 13,300 50180 Utebo, Zaragoza Ph. +34.97.646.2626 / 91.659.15.50 Fax +34.97.677.1560 SWITZERLAND RECORDATI S.A. Piazza Boffalora, 4 6830 Chiasso (CH) Ph. +41 91 682 6008 Fax +41 91 682 6009 TUNISIA OPALIA Pharma Z.I. Kalaat El Andalous 2022 Ariana Ph. +216 70 559 070-064 Fax +216 70 559 184 Email: [email protected] www.opaliapharma.com.tn TURKEY RECORDATI İLAÇ Sanayi - ve Ticaret A.S. Dogan Arasli Cad. No. 219 34510 Esenyurt-ISTANBUL Ph. +90 212 620 28 50 Pbx Fax +90 212 596 20 65 www.recordati.com.tr UKRAINE RECORDATI UKRAINE 40, Hlybochytska Str. - Kiev 04050 Ph. +380 44 351 18 63 Fax +380 44 351 18 64 UNITED KINGDOM RECORDATI PHARMACEUTICALS Ltd 200 Brook Drive, Green Park, Reading Berkshire RG2 6UB Tel/Fax: +44 1491 576336 Email: [email protected] UNITED STATES RECORDATI RARE DISEASES 100 Corporate Drive Lebanon, NJ 08833 Ph. +1 908 236 0888 Fax +1 908 236 0028 www.recordatirarediseases.com SPAIN ORPHAN EUROPE CASEN RECORDATI S.L. Via de las Dos Castillas, 33 Ática-Edificio 7 28224 Pozuelo, Madrid Ph. +34 91 351 88 00 (Lab. Casen Fleet) Fax +34 91 3518799 www.casenrecordati.com Immeuble "Le Wilson" 70, avenue du Général De Gaulle 92800 Puteaux, Francia Ph. +33 1 47 73 64 58 Fax +33 1 49 00 18 00 www.orphan-europe.com Email:[email protected] GREECE RECORDATI HELLAS PHARMACEUTICALS S.A. 7, Zoodochou Pigis str 15231 K. Chalandri, Atene Ph. +30 210 6773822 Fax +30 210 6773874 REC_BROCH_2016_INGLESE_Layout 1 09/06/16 10:39 Pagina 42 Industria Chimica e Farmaceutica S.p.A. HEADQUARTERS Via Matteo Civitali, 1 - 20148 Milan, Italy Ph +39 02 48 787.1 - Fax +39 02 40 073 747 www.recordati.com